Pfizer’s Vyndaqel, Vyndamax win US nod for rare disease
The approval is based on a clinical trial which showed that after an average of 30 months, the survival rate was higher in the Vyndaqel group.
Read More
Tag: transthyretin amyloid cardiomyopathy
- PMGroup Worldwide Ltd welcomes MAD World Summit
- Argenx receives review from FDA for VYVGART in seronegative gMG
- Nuclera extends Series C funding to advance antibody engineering
- Cellistic launches new iPSC-based platforms to expand immuno-oncology therapies
- Fabentech secures French approval for Ricimed antidote
